



NEWS RELEASE

## **RaQualia Receives an Allowance for an Acid Pump Antagonist Patent in the USA**

**October 10, 2013** - RaQualia Pharma Inc. (RaQualia) today announced that the company received a patent allowance\* for the uses of Acid Pump Antagonist (APA) in the U.S.A. (Application Number: 13/383,056).

The allowance grants a method for adjusting a gastrointestinal function or activating the gastrointestinal motility in a disease which abnormal gastrointestinal motility is involved with. The right is applied to APAs in general as well as the ones that RaQualia possesses, ensuring that the company's intellectual property rights will be strengthened in the U.S.A.

RaQualia licensed its APA project for East Asian rights to CJ CheilJedang (headquartered in Seoul, South Korea; CEO Kim Chul-ha) in September 2010, which is presently pursuing development in Korea.

APA has a different mechanism of action for suppressing gastric acid secretion than the proton pump inhibitor (PPI), the current therapy of choice for treating gastro-esophageal reflux disease (GERD). We anticipate APA will demonstrate faster and sustained gastric acid reduction when compared with PPI. APA is expected to improve GERD symptom control that is insufficiently addressed by PPI therapy. Moreover, it will have a possibility of being a new treatment for other acid-related digestive diseases like peptic ulcer.

RaQualia will continue its efforts to secure patents for APA in other regions, while it strengthens the licensing activities globally.

This step has little impact on RaQualia's Business Forecast issued on February 15, 2013.

\*A patent allowance is an evaluation by a country's patent office that a patent application merits being granted a patent. After the patent is allowed and the fee paid, it is registered and the patent is issued in the relevant country.

####